About This Deal

Gilead Sciences acquired CymaBay Therapeutics, Inc. for ~$4.3 billion, a transaction announced in February 2024.

Acquired the liver-disease specialist for $32.50 per share in cash (total equity value ~$4.3 billion) to add seladelpar, a PPAR-delta agonist for primary biliary cholangitis under FDA priority review, expanding Gilead's liver portfolio.

Acquired the liver-disease specialist for $32.50 per share in cash (total equity value ~$4.3 billion) to add seladelpar, a PPAR-delta agonist for primary biliary cholangitis under FDA priority review, expanding Gilead's liver portfolio.

Deal Terms

Acquirer
Gilead Sciences
Target
CymaBay Therapeutics, Inc.
Value
~$4.3 billion
Date
February 2024
Type
Full acquisition
Status
Completed

Transaction Details

Announced
February 11, 2024

In Their Words

We are looking forward to advancing seladelpar by leveraging Gilead's long-standing expertise in treating and curing liver diseases. -- Daniel O'Day, Chairman and CEO, Gilead Sciences

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.